Skip to main content
Download PDF

Protocol for MInimizing the Risk of Metachronous Adenomas of the CoLorectum with Green Tea Extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population

BMC Cancer volume 11, Article number: 360 (2011) Cite this article

Abstract

Background

Prevention of colorectal cancer is a major health care issue. People who have undergone colonoscopy screening and had colorectal polyps removed have a higher risk of being diagnosed with polyps again compared to the normal population. Therefore, it would be ideal to find appropriate means that effectively help to prevent the reoccurrence of polyps after polypectomy. So far, pharmaceutical chemoprevention with NSAIDs including aspirin has been shown to be effective but not gained general acceptance due to side effects. Nutraceuticals such as polyphenols from tea plants have demonstrated remarkable therapeutic and preventive effects in molecular, epidemiological and clinical trials. However, placebo-controlled trials demonstrating the efficacy of nutraceuticals for the (secondary) prevention of colorectal polyps as precursors for colorectal cancer are missing.

Methods/Design

We present the design of a randomized, placebo controlled, multicentre trial to investigate the effect of diet supplementation with green tea extract containing 300 mg epigallocatechin gallate (EGCG), the major polyphenol in green tea, on the recurrence of colon adenomas. Patients who have undergone polypectomy for colonic polyps will be randomized to receive either green tea extract containing 150 mg EGCG two times daily or a placebo over the course of three years. After a one month run-in period in which all patients will receive the active intervention, 2534 patients will be randomized, and 2028 patients are expected to complete the whole study course. Incidence, number and histology of adenoma at endpoint colonoscopy at three years will be compared in both groups.

Discussion

The beneficial safety profile of decaffeinated green tea extract, the quantifiable and known active content EGCG, and the accumulating evidence of its cancer preventive potential require, in our view, a validation of this compound for the nutriprevention of colorectal adenoma. Good accessibility and low costs might render this neutraceutical a top candidate for wider use as food supplement in colon cancer prevention.

Trial registration

ClinicalTrials.gov: NCT01360320

Peer Review reports

Background

The use of nutritional compounds for disease prevention and health maintenance is an emerging field, since nutritional products are usually less afflicted with the risk of severe side effects, and long-term experience in humans exists. Especially for cancer prevention, associations between diet and lifestyle have been established [1].

Green tea belongs to the oldest drinks of mankind, and its high levels of bioactive polyphenols provide the potential for therapeutic and preventive application. Supplementation of diet with green tea polyphenols as a nutraceutical has already been studied in the context of cancer, diabetes and cardiovascular disease [2–7].

About 30% of the content of green tea is polyphenols. The monomer flavan-3-ols are called catechins, and contribute to the astringent/bitter taste of green tea. Among all catechins in green tea the most important are 59% (-)-epigallocatechin-3-gallate (EGCG), 19% (-)-epigallocatechin (EGC), 13.6% (-)-Epicatechin-3-gallate (ECG), and 6.4% (-)-epicatechin (EC) [8].

Due to its presumed beneficial effects on cancer initiation and early cancer progression green tea polyphenols might be especially suited for cancer prevention rather than for cancer treatment [9]. The majority of colorectal cancers, the most frequent cancer type in men, shows a slow progression from normal mucosa to adenoma or advanced lesion (adenoma-carcinoma sequence), therefore allowing efforts for prevention of colorectal cancer [10]. Several studies on the chemoprevention of colorectal cancer have been performed using compounds such as acetyl salicylic acid (ASS) or cyclooxygenase (COX) isoenzyme 2-specific nonsteroidal anti-inflammatory agents (NSAIDs) [11–17]. NSAIDs seem to have a beneficial effect in preventing the development and/or recurrence of adenomas. However, the benefit risk ratio of daily use of these agents over years does not seem to justify a broad use for primary or secondary chemoprevention due to adverse effects such as gastrointestinal hemorrhage, peptic ulcers and potential cardiovascular toxicity [18]. Therefore, COX inhibitors have been accepted as chemopreventive agents only for patients with a very high risk of developing colorectal cancer, such as those with familial adenomatous polyposis [19].

Green tea extract and its major active component EGCG have been studied in several models for their preventive properties on the development of colon adenomas. In the Apcmin mouse, a model for colon adenoma development, a tremendous effect on the number and growth of adenomas was detected upon feeding the animals with EGCG-supplemented drinking water [20, 21].

In addition, EGCG even inhibits the growth of established human colorectal cancer cells and induces apoptosis, which is accompanied by inhibition of COX-2 expression and reduced activation of the epidermal growth factor receptor tyrosine kinase family [22, 23].

One small pilot study on the supplementation of green tea consumption with capsules containing green tea extract in Japanese patients with a history of colon adenomas resulted in a 50% reduction of the incidence of metachronous adenomas in the supplementation group compared to the placebo group after one year [9]. Epidemiological studies in Asian countries also point to a preventive effect on colon cancer from high daily intake of green tea (more than 5 cups daily) [24, 25].

Since green tea extract - in contrast to green tea itself - is decaffeinated, diet supplementation with EGCG from green tea extract may constitute a nutriprevention with an extremely favorable safety profile. We report here on the design of a large, placebo-controlled prospective trial on the effect of diet supplementation with EGCG on colorectal adenoma prevention.

Methods/Design

Design and setting

The trial follows a prospective randomized controlled design comparing the twice daily intake of green tea extract containing 150 mg EGCG supplement to a placebo. Patients will be randomized after a verum run-in period of one month to receive either green tea extract containing 150 mg EGCG two times daily or placebo over the course of three years.

Study outcomes

Primary outcome

The primary outcome parameter will be the incidence of any (n equal to or larger than 1) metachronous colorectal adenomas (tubulovillous, tubular, villous and serrated lesions) at the 3 year follow-up colonoscopy in both groups.

Secondary outcomes

The occurrences, number, localization, size and histological subtypes of adenomas or mucosal lesions and invasive growth, as well as the time to detection of new colorectal carcinoma (assuming that in several patients more than one colonoscopy will be performed within 3 years) and the frequency of carcinoma, will be assessed as secondary outcome parameters in both groups. In addition, genetic and biochemical biomarkers for the recurrence of adenoma or the development of dysplasia and carcinoma will be analyzed in the blood samples entered into the biobanking subproject. Paraffin-embedded tissue samples will be collected in participants who show a high grade dysplastic adenoma or serrated adenoma at the follow-up colonoscopy. In these samples, besides the histological analyses the possibly therapeutically relevant tumor-genetical alterations including K-ras mutation, B-raf mutation or specific microRNA will be analyzed.

In an independent project, the nutrikinetics and nutrigenetics of EGCG and other green tea catechins will be assessed in healthy volunteers with the capsules used in this study.

Sample size calculation

The sample size estimation was derived from the existing chemopreventive studies reporting a re-incidence of metachronous adenomas of about 45% at follow-up colonoscopy [13]. Assuming an effect similar to that observed for ASS, chemoprevention might lead to a relative risk reduction of 12% [13]. Therefore, if ECGC intake leads to a similar relative risk reduction of 11% and if there is a recurrence of adenomas in 45% of the patients in the placebo group, 40% of the patients taking green tea extract should have a recurrent adenoma after three years. Sample size estimation was performed using the Mantel-Haenszel test stratifying for the use of low-dose ASS, assuming that 20% of the study participants will be on low-dose (≤ 100 mg) ASS due to the frequent use of low-dose ASS in the age group of the participants (50 years and above). Assuming a recurrence rate of 38.3% in the combined verum green tea and low-dose ASS arm, and of 47.1% in the placebo/no ASS group, a sample size of n = 1203 (both in verum and placebo) is required for the intention to treat (ITT) sample with significance level of 5% and a power of 80% (stratified one-sided Mantel-Haenszel test, NQUERY 7.0 software, Statistical Solutions, Cork, Ireland).

Assuming a drop-out rate of 5% of patients for the control colonoscopy, 1267 randomized patients per arm will be required, resulting in randomization of 2534 patients after the run-in period.

A drop-out rate of 20% is assumed for regular capsule intake. Thus, 1014 patients will be evaluable for the per-protocol analysis of the green tea effect. For exploratory analysis of potential confounders, this sample size is sufficient to include 30-40 variables inclusive dummy-coding with around 20 events per variable into the model.

Participants

The study will be performed nationwide in Germany. Patients will be recruited from gastroenterological centers that are performing a high number of screening and interventional colonoscopies. Participants undergoing screening colonoscopy who are diagnosed with colorectal adenomas will be randomized within 6 months after polypectomy if they give informed consent. Participants who are willing to participate in the trial will undergo a short screening interview and then enter the run-in phase of 4 weeks, in which all participants of the trial will receive verum. This run in-phase is designed to obtain information about potential and unforeseen side effects of green tea extract intake that might affect the well-being of the participants or the blinding of the trial. Randomization will follow after a successful run-in period. Participants who are not compliant to the study protocol or do not tolerate the green tea extract supplementation will not be randomized.

As judged from similar trials, we expect a 15% dropout rate after run-in. Thus, 2941 participants will be included in the run-in phase in order to achieve a total number of 2534 randomized participants (Figure 1).

Figure 1
figure 1

Flow Diagram of the progress through the phases of the study. Assuming a drop-out rate of 5% of patients for the control colonoscopy, 1267 randomized patients per arm will be required, resulting in randomization of 2534 patients after the run-in period. 1203 patients per arm are expected to be available for the ITT analysis undergoing control colonoscopy after three years. A drop-out rate of 20% is assumed for regular capsule intake. Thus, 1014 patients will be evaluable for the per-protocol analysis of the green tea effect.

Full size image

In Germany, about 500,000 individuals undergo screening colonoscopies each year. A large colonoscopy center typically performs more than 3000 colonoscopies per year. In 10-15% of these screenings, adenomas are detected and removed. We expect that about half of these cases will be eligible for study inclusion. About 30 colonoscopy centers will take part in this study, in order to allowing us to recruit the planned number of participants in the intended 3-year period.

Inclusion & exclusion criteria

Interested persons are eligible for study participation if they are between 50-80 years of age, and have had histologically confirmed colorectal adenomas or serrated lesions removed during colonoscopy within the last 6 months. All participants of the study must be in good performance status at study entrance, corresponding to a level below 2 in the ECGG performance status scale [26]. Only patients able to give informed consent will be included after written informed consent.

Exclusion criteria for study participation are a history of hereditary nonpolyposis colorectal cancer (HNPCC) or familial adenomatous polyposis (FAP), a history of colorectal cancer or other concomitant cancers with the exception of basal cell carcinoma or curative treated cancers without actual anticancer medication. In addition, interested parties with intestinal malabsorption, short bowel syndrome or surgical bowel interventions leading to malabsorption will not be included into the study. Liver failure (hepatitis, cirrhosis), elevation of the liver enzymes ALT, AST or bilirubin to more than 2.5-fold above the upper normal value or inflammatory bowel disease are also exclusion criteria.

Regular intake of NSAIDs (including Cox-2 inhibitors) for more than 3 months per year, with the exception of low-dose ASS (≤ 100 mg per day), is not compatible with study participation. In addition, individuals who are on immunosuppressive medication are excluded from the study.

Individuals with impaired capacity to consent or who are impaired in swallowing pills will not be eligible for study participation.

In addition, subjects who have regularly consumed green tea extract with an EGCG content of more than 100 mg per day as a nutritional supplement for more than six months during the past two years will be excluded, as will individuals who have shown allergic reactions to green tea or its extract.

Patient information and allocation

Informed consent is obtained after written and oral information by a study physician prior to inclusion into the study. The potential participants must fully understand all possible implications of the study, and all their questions must be answered sufficiently. After written informed consent, participants will be included into the one month run-in period where all participants receive 2 × 150 mg EGCG daily over 4 weeks. At study inclusion and after this period, liver enzymes (AST, ALT, bilirubin) will be checked and patients who either have more than 20 capsules (out of 64) left or have elevated liver enzymes of more than 2.5-fold of the upper normal value will be excluded from the study.

After the one month run-in period with ECGC, patients will be assessed and randomized to either the intervention group, which will receive green tea extract containing 300 mg EGCG per day, or to the control group, which will receive a placebo capsule twice daily.

Blinding and randomization

Stratified randomization based on study centers and on regular intake of low-dose ASS (yes or no) will be performed with the software ROM [27] to achieve balance of these baseline covariates. There will be no further stratification, since it is assumed that with a sample size of n = 1203 per group for the ITT collective, covariates like green tea consumption, age, sex, family history of colon cancer, medication and lifestyle will be equally distributed in both study arms.

Recruitment will be competitive and concurrent in about 30 colonoscopy screening centers throughout Germany. It will be assumed that each study center will recruit at least 30 patients per year.

Patients and physicians including the study coordinators will be fully blinded to the study substance. An independent pharmaceutical contract manufacturer specializing in solid pharmaceutical dosing forms will produce the placebo and EGCG capsules, and will dispense them according to a randomization list. Patients included into the run-in phase will be notified by a fax to the study coordinating center.

Randomization will take place after a successful run-in period, and a random study number will be assigned to each participant. The study substance for the first three months (three packages containing 70 blistered capsules each) will then be sent out during one week after the end of the run-in period. Study start is the first day of intake of the study substance.

Study procedures

Green tea extract

Powdered decaffeinated green tea extract will be prepared from the young unfermented leaf and leaf buds of Camellia Sinensis (L.) Kuntze (Fam. Theaceae) imported from China. The normally associated caffeine found in lower grade tea catechin mixtures will be eliminated to less than 0.5% content in the extract. The extract will be prepared using ethanol, methanol, acetone or water, as solvents. Microbiological and toxicological analyses are done to control for degradation products, pesticides, herbicides, polyaromatic hydrocarbons, and other unacceptable contaminants.

The study material will be packed in hard gelatine capsules containing either green tea extract (150 mg EGCG) or placebo, and pharmaceutical excipients consisting of microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. The caffeine content of the green tea extract used to prepare the capsules will be maximally 0.5% and thus the caffeine content of one capsule will be below 1.5 mg.

Dose determination

The application of green tea extract standardized to a twice daily dose of 150 mg EGCG was decided upon a review of the existing literature on clinical long-term prevention studies and the rationale that a nutriprevention study should involve doses corresponding to nutritional use of green tea for which there is at least some epidemiological evidence for a cancer-preventive action.

A simple calculation shows that a daily dose of 300 mg EGCG corresponds to a normal intake of green tea: one cup of green tea is brewed with approximately 2 g of tea leaves. Tea leaves have a catechin content of about 10%. If the tea is brewed for 10 min, about 80% of the catechins will have dissolved. The amount of EGCG is about 50% of the catechins. This means that one cup of this green tea would contain about 80 mg EGCG, and the same amount of other dissolved catechins. Thus, 300 mg would correspond to 4 cups of tea brewed with this method. In practice, tea may be brewed with a shorter duration, which would result in a lower concentration of catechins. Thus, the daily dose applied in this study certainly lies within the range of 4-7 cups of tea per day, which is still a physiological dose.

A check with the literature reveals that in all existing long term studies, similar doses have been given (see table 1).

Table 1 summary of long term (≥ 2 weeks) interventional studies with green tea extract
Full size table

Side effects and contraindications

There are no known common side effects of green tea extract. A systematic review performed in 2008 by the United States Pharmacopeia, case reports and animal pharmacology/toxicology studies from 1966 to 2007 showed no clear evidence for EGCG-related toxicity, specifically liver enzyme elevation in a common dose range of up to 800 mg [28]. A total of 216 case reports on green tea products were analyzed, including 34 reports concerning liver damage. Twenty-seven reports pertaining to liver damage were categorized as possible causality and seven as probable causality [28]. Consumption of concentrated green tea extract on an empty stomach is more likely to lead to adverse effects than consumption in the fed state, since up to five-fold higher plasma concentrations have been observed with empty stomach compared to the fed state [29–31]. In our study, liver enzyme parameters will be tested prior to enrollment, after the one month run-in period and after 4, 12, 20 and 36 months, respectively. An increase of liver enzymes by 2.5-fold above the upper normal value will lead to discontinuation of the study medication. Participants will be urged to take the capsules at breakfast and dinner. There are no known contraindications for the intake of green tea extract. Nevertheless, we will test for hepatotoxicity after one month of EGCG intake.

Interactions

The potential of EGCG to induce drug-drug interactions by the inhibition of major human cytochrome P450 isoenzymes has been studied in vitro using isoform-selective probe substrates for the major human CYP450 isoforms involved in drug-metabolism (CYP1A2, 2C9, 2C19, 2D6 and 3A4) [32]. Based on these in vitro results, no significant interactions are expected in man for EGCG with concomitantly administered compounds mainly metabolized by CYP1A2, CY2C9, CYP2C19, CYP2D6 and CYP3A4. Interactions via inhibition of transporters such as P glycoprotein or Multidrug Resistance Protein (MRP) by EGCG is possible, but has not been reported so far.

Study visits

Every four months during the 36 months of the whole study, the participants will be asked to visit the gastroenterological centers to check for any adverse events and medication changes, and to confirm with the physician the regular intake of the study medication. Blood sampling for liver enzyme testing will be performed after run in, and at the 4, 12, 20 and 36 month visits, and at 4, 20 and 36 months for biomarker sampling.

Data on health status, medication, and complaints about the study substance will be collected and the study diary will be reviewed. After each clinical visit, the study medication for the next study period will be dispensed. In cases of non-compliance or any disruption longer than four months of intake of EGCG, the study investigators will decide whether the participant may continue in the study.

The final study visit will be for the control colonoscopy three years after the start of the study. If additional colonoscopies have been performed during the three year interval, the results of those will be documented as well. The results of the colonoscopy as well as the histological confirmation of potential metachronous colorectal adenomas will be documented, as well as clinical data on medication, health status, complaints and adherence to capsule intake.

Follow-up visits are planned for three and six years after the end of the study in order to assess the long term development of adenomas since we know that it may take years to see the effect of a preventive treatment. As an example, the effect of ASS chemoprevention on colon carcinoma was assessed 10 years after [33].

Drop-out criteria

In the following situations, no study enrollment after the run-in is foreseen:

  • If the pill count after the run-in period contains more than 30 capsules (out of 70 capsules).

  • If the liver enzyme parameters are elevated above 2.5-fold of the upper normal value.

  • Study participation will be terminated in the following occasions:

  • in the case of any severe adverse event impairing further participation in the study

  • If the adherence to study medication is poor (if > 35% of the capsules were not taken during more than one study period)

  • the regular intake of the capsules is not assured, for any reason

  • it becomes evident after the enrollment that the inclusion criteria have not been fulfilled

  • a continuous (longer than 3 months) intake of the following drugs has become necessary: Any NSAID including COX-2 selective NSAIDs and ASS in a dose higher than 100 mg

  • the patients desires to exit the study

  • The liver enzyme parameters are elevated more than 2.5-fold of the upper normal value.

It is intended to include the data of the follow-up colonoscopy in the subjects that have dropped out for the intention-to-treat analysis.

Biobanking

At time points prior to the run-in period, and after 4, 20 and 36 months, blood sampling for biobanking will be performed. The biobank will consist of pseudonymized (coded) plasma, serum and whole blood samples for biomarkers for adenoma development, as well as paraffin blocks of advanced adenomas detected in study participants at the 3 year colonoscopy. Participation in the clinical trial is independent from the biobanking project, and thus, separate informed consent will be given for the biobanking project.

Ethics

The MIRACLE study will be performed according to the study protocol, as well as the ICH-GCP criteria, the Declaration of Helsinki, EU directives and applicable legal requirements. The study has been approved by Ethical Review Boards of the Martin Luther University of Halle-Wittenberg and Ulm University (Application 68/09, approved on the 9th of April 2009).

Data collection

Information on each patient's age, gender, height, weight, waist-to-hip ratio, ethnicity, regular tea intake, sport and activity level, smoking state, alcohol intake, family history of colon cancer and current disease and medication will be obtained from the initial interview before the run-in phase. From the colonoscopy prior to study entry, data on the number, localization and size of the removed adenoma(s) as well as the histological subtype and history of prior colonoscopies will be assessed. The patients' attitudes towards medicine and herbal supplements will be assessed at the beginning of the study.

At the follow-up visits, data on changes in concurrent disease or drug therapy, data on regular intake of the study medication and green tea beverages, laboratory data on liver enzymes and any adverse events experienced during the study will be recorded.

At the final visit, weight, waist-to-hip ratio, regular tea intake, data on changes in disease and medication will be obtained as well as data from the follow-up colonoscopy on the number, localization and size of the removed adenoma(s) as well as the histological subtype.

Data management

Data management, query management and monitoring of the study will be done by the Coordination Center for Clinical Trials at the Martin Luther University of Halle-Wittenberg (KKSH). Data collection will be done on paper CRFs and will be entered and stored in a validated GCP conform database. Study monitoring will be performed with one on-site visit per study center and regular data-entry checks of the CRFs.

Statistical analysis

The trial results will be analyzed by intention-to-treat and the per-protocol analysis. In analogy to [15] a modified intention-to-treat approach will be performed including all randomized subjects with a follow-up colonoscopy, irrespective of adherence to the study medication. Lacking values will be estimated using the Multiple Imputation MCMC method [34].

The per-protocol analysis will be done in all subjects who completed the whole course of the study. Safety will be assessed in all patients who took at least one capsule of the study medication.

Statistical analysis of the primary outcome

The study's aim is to check the following hypothesis: the regular intake of green tea extract (at least 300 mg daily) over three years results in a decrease of the incidences of colorectal adenomas. This primary outcome based on the intention-to-treat-population will be tested confirmatively by the one-sided χ2-Test [35] with a significance level of 5%.

The impact of other variables (e. g. study center, intake of low-dose ASS) related to the recurrence of adenomas will be explorative controlled by the logistic regression model [36]. Concerning the time of the recurrence of adenomas, the impact of other variables will be explorative controlled with the Cox proportional hazard model [37].

With the help of this multivariate analysis both the relative risks and the 95% confidence-intervals can be calculated.

Statistical analyses of the secondary outcome

How much other impact factors affect the risk of the incidence of metachronous adenomas will be analyzed explorative.

In addition, genetic and biochemical biomarkers for the recurrence of adenomas or the development of dysplasia and carcinoma will be analyzed explorative in the blood samples entered into the biobanking subproject.

Time plan

Patient recruitment is planned for a period of three years starting in October 2011. The total duration of the trial will be six years, with the last patient out in fall 2017.

Discussion

The aim of this large prevention trial is to study the influence of regular nutritional supplementation with green tea extract containing EGCG, one of the active components of green tea, on the incidences of metachronous colorectal adenomas in subjects who have undergone polypectomy. Thus, it is a secondary prevention trial

The limitation of prior large-scale chemoprevention trials, when administering drugs like ASS or COX-2 inhibitors to a large group of healthy individuals for long term treatment, was safety. Even if the trials were successful with respect to their primary endpoint, prevention of metachronous colorectal adenomas, the clinical utility of NSAIDs used for this indication is rather low due to the unwanted side effects of these drugs.

This is the first large-scale controlled prevention trial using nutritional supplement as the active principle. The dose of ECGC in our green tea extract was chosen to mimic high and regular green tea consumption without the influence of caffeine. While we are aware that 300 mg ECGC per day is lower than the dose range in some trials (with multiple dose data of up to 800 mg per day), we chose this dose because it corresponds to a somewhat physiological intake of green tea of about 4-7cups per day, and because this dose is intended for use over an extended period of time, i.e. three years.

Of course, the mere act of taking a capsule two times a day might discourage some individuals from performing an individual preventive plan, but in principle this would be possible, and could be a recommendation for a broader target audience.

There are some data indicating that the other polyphenols in green tea may also contribute to its beneficial effects. Therefore we chose to use green tea extract containing a defined amount of ECGC but also the other polyphenols that are found in green tea.

We believe that a randomized controlled trial design is the only appropriate method to perform such a preventive trial, and justifies the efforts of such a trial. The limitations of the trial are the relatively short time period for follow-up (three years is short compared to the adenoma carcinoma sequence), the lack of a regular adherence measurement (ECGC does not accumulate and has a short half life, and therefore there is no long term parameter for the intake of EGCG), and the risk of a higher than presumed drop-out rate. However, the beneficial safety profile of green tea extract, and the widespread evidence on its cancer preventive potential, justifies in our view a validation of this compound for the nutriprevention of colorectal adenoma. Good accessibility and low costs might render this neutraceutical a top candidate for a wider use as food supplement in colon cancer prevention.

Abbreviations

ASS:

Acetyl salicylic acid/

COX:

Cyclooxygenase

CRF:

Case report forms

CYP450:

Cytochrome P450 enzyme

EC:

Epicatechin

ECG:

Epicatechin-3-gallate

EGC:

Epigallocatechin

EGCG:

Epigallocatechin gallate

FAP:

Familial adenomatous polyposis

GCP:

Good clinical practice

HNPCC:

Hereditary nonpolyposis colorectal cancer

ICH:

International conference of harmonization

MIRACLE:

Minimizing the Risk of Metachronous Adenomas of the Colorectum with Green Tea Extract Study

MRP:

Multidrug Resistance Protein

NSAID:

Nonsteroidal anti-inflammatory drug.

References

  1. Cancer WCRFAIf, Research: Food, Nutrition, and Physical Activity, and the Prevention of Cancer: A Global Perspective. 2007, Washington, DC: AICR

    Google Scholar 

  2. Widlansky ME, Hamburg NM, Anter E, Holbrook M, Kahn DF, Elliott JG, Keaney JF, Vita JA: Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr. 2007, 26 (2): 95-102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, Tsubono Y, Tsuji I: Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. Jama. 2006, 296 (10): 1255-1265. 10.1001/jama.296.10.1255.

    Article  CAS  PubMed  Google Scholar 

  4. Cabrera C, Artacho R, Gimenez R: Beneficial effects of green tea--a review. J Am Coll Nutr. 2006, 25 (2): 79-99.

    Article  CAS  PubMed  Google Scholar 

  5. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ: Dietary polyphenolic phytochemicals--promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer. 2007, 120 (3): 451-458. 10.1002/ijc.22419.

    Article  CAS  PubMed  Google Scholar 

  6. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE: Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol. 2009, 27 (23): 3808-3814. 10.1200/JCO.2008.21.1284.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Fukino Y, Ikeda A, Maruyama K, Aoki N, Okubo T, Iso H: Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J Clin Nutr. 2008, 62 (8): 953-960. 10.1038/sj.ejcn.1602806.

    Article  CAS  PubMed  Google Scholar 

  8. McKay DL, Blumberg JB: The role of tea in human health: an update. J Am Coll Nutr. 2002, 21 (1): 1-13.

    Article  CAS  PubMed  Google Scholar 

  9. Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki H: Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev. 2008, 17 (11): 3020-3025. 10.1158/1055-9965.EPI-08-0528.

    Article  CAS  PubMed  Google Scholar 

  10. Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet. 1993, 9 (4): 138-141. 10.1016/0168-9525(93)90209-Z.

    Article  CAS  PubMed  Google Scholar 

  11. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, Omary MB: Effect of sulindac on sporadic colonic polyps. Gastroenterology. 1995, 108 (4): 1083-1087. 10.1016/0016-5085(95)90206-6.

    Article  CAS  PubMed  Google Scholar 

  12. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003, 348 (10): 883-890. 10.1056/NEJMoa021633.

    Article  CAS  PubMed  Google Scholar 

  13. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003, 348 (10): 891-899. 10.1056/NEJMoa021735.

    Article  CAS  PubMed  Google Scholar 

  14. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S: Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003, 125 (2): 328-336. 10.1016/S0016-5085(03)00887-4.

    Article  CAS  PubMed  Google Scholar 

  15. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG: A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006, 131 (6): 1674-1682. 10.1053/j.gastro.2006.08.079.

    Article  CAS  PubMed  Google Scholar 

  16. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006, 355 (9): 873-884. 10.1056/NEJMoa061355.

    Article  CAS  PubMed  Google Scholar 

  17. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006, 355 (9): 885-895. 10.1056/NEJMoa061652.

    Article  CAS  PubMed  Google Scholar 

  18. Half E, Arber N: Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother. 2009, 10 (2): 211-219. 10.1517/14656560802560153.

    Article  CAS  PubMed  Google Scholar 

  19. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007, 146 (5): 365-375.

    Article  PubMed  Google Scholar 

  20. Ju J, Hong J, Zhou JN, Pan Z, Bose M, Liao J, Yang GY, Liu YY, Hou Z, Lin Y, Ma J, Shih WJ, Carothers AM, Yang CS: Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res. 2005, 65 (22): 10623-10631. 10.1158/0008-5472.CAN-05-1949.

    Article  CAS  PubMed  Google Scholar 

  21. Issa AY, Volate SR, Muga SJ, Nitcheva D, Smith T, Wargovich MJ: Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model. Carcinogenesis. 2007, 28 (9): 1978-1984. 10.1093/carcin/bgm161.

    Article  CAS  PubMed  Google Scholar 

  22. Peng G, Dixon DA, Muga SJ, Smith TJ, Wargovich MJ: Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog. 2006, 45 (5): 309-319. 10.1002/mc.20166.

    Article  CAS  PubMed  Google Scholar 

  23. Shimizu M, Deguchi A, Joe AK, McKoy JF, Moriwaki H, Weinstein IB: EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol. 2005, 5 (1): 69-78.

    PubMed  Google Scholar 

  24. Sun CL, Yuan JM, Koh WP, Yu MC: Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis. 2006, 27 (7): 1310-1315. 10.1093/carcin/bgi276.

    Article  CAS  PubMed  Google Scholar 

  25. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K: Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors. 2000, 13 (1-4): 49-54. 10.1002/biof.5520130109.

    Article  CAS  PubMed  Google Scholar 

  26. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5 (6): 649-655. 10.1097/00000421-198212000-00014.

    Article  CAS  PubMed  Google Scholar 

  27. Rohlmann F, Muche R, Goldschmidt L: Randomisierung in klinischen Studien: Praktische Umsetzung mit dem Randomisationsprogramm ROM. 2004, Ulm: Universitätsverlag Ulm

    Google Scholar 

  28. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI, Low Dog T: Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf. 2008, 31 (6): 469-484. 10.2165/00002018-200831060-00003.

    Article  PubMed  Google Scholar 

  29. Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS, Pineau B, Weber P: A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res. 2003, 31 (2): 88-101.

    Article  CAS  PubMed  Google Scholar 

  30. Chow HH, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, Hara Y: Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev. 2001, 10 (1): 53-58.

    CAS  PubMed  Google Scholar 

  31. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS: Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. 2003, 9 (9): 3312-3319.

    CAS  PubMed  Google Scholar 

  32. Netsch MI, Gutmann H, Schmidlin CB, Aydogan C, Drewe J: Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med. 2006, 72 (6): 514-520. 10.1055/s-2006-931537.

    Article  CAS  PubMed  Google Scholar 

  33. Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007, 369 (9573): 1603-1613. 10.1016/S0140-6736(07)60747-8.

    Article  CAS  PubMed  Google Scholar 

  34. Tanner MA, WWH: The Calculation of Posterior Distributions by Data Augmentation. Journal of the American Statistical Association. 1987, 18: 528-540.

    Article  Google Scholar 

  35. Bland M: An introduction to medical statistics. 2000, New York: Oxford University Press

    Google Scholar 

  36. Hosmer D, Lemeshow S: Applied logistic regression. 2000, New York.: Wiley

    Chapter  Google Scholar 

  37. Kleinbaum DG: Survival Analysis - A self learning text. 1996, New York.: Springer

    Google Scholar 

  38. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A: Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006, 66 (2): 1234-1240. 10.1158/0008-5472.CAN-05-1145.

    Article  CAS  PubMed  Google Scholar 

  39. Kajimoto O, Kajimoto Y, Yabune M, Nakamura T, Kotani K, Suzuki Y, Nozawa A, Nagata K, Unno T, Sagesaka Y, Kakuda T, Yoshikawa T: Tea Catechins with a Galloyl Moiety Reduce Body Weight and Fat. Journal of Health Science. 2005, 51 (2): 161-171. 10.1248/jhs.51.161.

    Article  CAS  Google Scholar 

  40. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA: Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2009, 2 (7): 673-682. 10.1158/1940-6207.CAPR-08-0167.

    Article  CAS  Google Scholar 

Pre-publication history

Download references

Acknowledgements

This trial is financed by the German Cancer Aid Grant No 109122. Many thanks to Valerie O'Brien for language revision of the manuscript.

Author information

Authors and Affiliations

  1. Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Germany

    Julia C Stingl & Angela Seeringer

  2. Department of Internal Medicine I, University Hospital, Martin-Luther-University Halle-Wittenberg, Germany

    Thomas Ettrich & Thomas Seufferlein

  3. Institute of Epidemiology and Medical Biometry, University Ulm, Germany

    Rainer Muche & Martina Wiedom

  4. Department of Clinical Pharmacology, University Göttingen, Germany

    Jürgen Brockmöller

Authors
  1. Julia C Stingl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Ettrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rainer Muche
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martina Wiedom
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jürgen Brockmöller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angela Seeringer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas Seufferlein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia C Stingl.

Additional information

Competing interests

None of the authors has any competing interest (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript.

Authors' contributions

JS conceived of the study (together with TS) and drafted the manuscript. TE participated in the design and coordination of the study and helped to draft the manuscript. RM planned the sample size estimation, trial analysis and randomization and participated in the study design. MW participated in the statistical aspects of the study design and developed the randomization plan. JB prepared the nutrikinetic parts of the study, carried out the plasma analytics kinetic data analyses and participated in the design of the study. AS participated in the design and planning of the study. TS is the principal investigator and conceived of the study (together with JS) and drafted the manuscript. All authors read and approved the final manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Stingl, J.C., Ettrich, T., Muche, R. et al. Protocol for MInimizing the Risk of Metachronous Adenomas of the CoLorectum with Green Tea Extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. BMC Cancer 11, 360 (2011). https://doi.org/10.1186/1471-2407-11-360

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/1471-2407-11-360

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us